Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.

ABSTRACT:

Background

Although implantable cardioverter-defibrillator (ICD) therapy reduces mortality in moderately symptomatic heart failure patients with an ejection fraction Methods and resultsUsing a modification of a previously validated risk prediction model based on routine clinical variables, we examined the relationship between baseline predicted mortality risk and the relative and absolute survival benefits of ICD treatment in the primary prevention Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). In the placebo arm, predicted 4-year mortality grouped into 5 equal-sized risk groups varied from 12% to 50% (c statistic=0.71), whereas the proportion of SCD in those same risk groups decreased

SUBMITTER: Levy WC 

PROVIDER: S-EPMC3774781 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature